Encompass Health Corp (AMEX:EHC) – Equities research analysts at Piper Sandler lifted their Q3 2020 earnings per share estimates for Encompass Health in a research note issued to investors on Tuesday, July 28th. Piper Sandler analyst S. James now anticipates that the company will earn $0.89 per share for the quarter, up from their prior forecast of $0.80. Piper Sandler also issued estimates for Encompass Health’s Q1 2021 earnings at $1.02 EPS, Q2 2021 earnings at $1.08 EPS and Q3 2021 earnings at $0.98 EPS.
A number of other equities analysts have also issued reports on the company. BMO Capital Markets increased their price objective on Encompass Health from $66.00 to $83.00 and gave the stock an “outperform” rating in a report on Monday, April 20th. Royal Bank of Canada reissued a “buy” rating and issued a $84.00 price objective on shares of Encompass Health in a report on Monday, April 20th. Jefferies Financial Group decreased their price objective on Encompass Health from $90.00 to $86.00 and set a “buy” rating for the company in a report on Monday, July 27th. Credit Suisse Group reissued a “buy” rating and issued a $89.00 price objective on shares of Encompass Health in a report on Wednesday, June 10th. Finally, Mizuho decreased their price objective on Encompass Health from $90.00 to $87.00 and set a “buy” rating for the company in a report on Friday, May 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $85.71.
Encompass Health has a fifty-two week low of $40.86 and a fifty-two week high of $59.29.
Encompass Health (AMEX:EHC) last posted its earnings results on Monday, July 27th. The company reported $0.31 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.39 by ($0.08). The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. The company’s revenue was down 7.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.08 earnings per share.
In other news, CEO Mark J. Tarr sold 26,132 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $61.92, for a total transaction of $1,618,093.44. Following the completion of the sale, the chief executive officer now owns 409,197 shares in the company, valued at approximately $25,337,478.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be given a dividend of $0.28 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.12 dividend on an annualized basis and a dividend yield of ∞.
Encompass Health Company Profile
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services. The company operates through two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Featured Article: Municipal Bonds
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.